Fyn expression is associated with the response of patients with locally advanced uterine cervical squamous cell carcinoma to neoadjuvant chemotherapy.
Fyn
neoadjuvant chemotherapy
uterine cervical cancer
Journal
Molecular and clinical oncology
ISSN: 2049-9469
Titre abrégé: Mol Clin Oncol
Pays: England
ID NLM: 101613422
Informations de publication
Date de publication:
Oct 2022
Oct 2022
Historique:
received:
14
06
2022
accepted:
29
07
2022
entrez:
26
9
2022
pubmed:
27
9
2022
medline:
27
9
2022
Statut:
epublish
Résumé
Neoadjuvant chemotherapy (NAC) followed by surgery is the current standard of treatment for locally advanced uterine cervical cancer; however, its value and outcomes remain contested. Identifying biomarkers that allow for the prediction of the effect of NAC efficacy before initiation of treatment is essential, in order to assist in choosing the optimum therapeutic regimen to maximize the beneficial outcomes of treatment. In the present retrospective study, 44 patients with locally advanced uterine cervical squamous cell carcinoma who underwent NAC were divided into two groups: A NAC successful group and a NAC failure group, depending on the efficacy of NAC. Subsequently, the association between Fyn expression, a non-receptor tyrosine kinase that is a member of the Src family kinases, and NAC efficacy was determined; Fyn expression was detected by immunohistochemistry and assessed using a weighted scoring method. Additionally, the effect of Fyn knockdown on the sensitivity of a uterine cervical cancer cell line to cisplatin was determined. Notably, there were no significant differences between the two groups of patients regarding their characteristics. Regarding overall survival, the NAC successful group had a significantly longer survival time than the NAC failure group (P=0.01). Furthermore, the expression levels of Fyn in tumor tissues were significantly lower in the NAC successful group compared with those in the NAC failure group (P=0.003). The patients were subsequently divided into two groups (high expression group and low expression group) according to a cutoff value of 3, which was determined by producing a receiver operating characteristic curve from the weighted scores. The low expression group was significantly more sensitive to NAC than the high expression group (P<0.001).
Identifiants
pubmed: 36157319
doi: 10.3892/mco.2022.2580
pii: MCO-17-4-02580
pmc: PMC9468808
doi:
Types de publication
Journal Article
Langues
eng
Pagination
147Informations de copyright
Copyright: © Nanno et al.
Déclaration de conflit d'intérêts
The authors declare that they have no competing interests.
Références
Oncotarget. 2014 Sep 15;5(17):7776-87
pubmed: 25277200
Annu Rev Cell Dev Biol. 1997;13:513-609
pubmed: 9442882
Data Brief. 2015 Jul 06;4:384-9
pubmed: 26217821
Oncotarget. 2014 Mar 15;5(5):1304-14
pubmed: 24675421
Pharmacol Res. 2015 Oct;100:250-4
pubmed: 26305432
Bioorg Med Chem Lett. 2007 Feb 1;17(3):602-8
pubmed: 17113292
Eur J Pharmacol. 2018 Nov 15;839:66-75
pubmed: 30266665
Oncologist. 2003;8(6):531-8
pubmed: 14657531
Oncogene. 2011 Dec 1;30(48):4814-23
pubmed: 21625209
Oncogene. 2003 Oct 20;22(47):7265-79
pubmed: 14576837
BMC Cancer. 2022 Apr 9;22(1):380
pubmed: 35397600
Int J Clin Oncol. 2016 Dec;21(6):1120-1127
pubmed: 27342833
Neuro Oncol. 2020 Jun 9;22(6):806-818
pubmed: 31950181
Biomed Pharmacother. 2019 Apr;112:108654
pubmed: 30784933
Cancers (Basel). 2022 Feb 08;14(3):
pubmed: 35159111
Virchows Arch. 2005 Sep;447(3):626-33
pubmed: 15968547
Oncol Rep. 2000 Jan-Feb;7(1):141-4
pubmed: 10601608
Oncol Lett. 2021 Nov;22(5):755
pubmed: 34539859
Cancer. 2010 Apr 1;116(7):1629-37
pubmed: 20151426
CA Cancer J Clin. 2022 Jan;72(1):7-33
pubmed: 35020204
Int J Oncol. 2017 Jul;51(1):169-183
pubmed: 28560430
Int J Gynecol Cancer. 2010 May;20(4):611-6
pubmed: 20686381
Oncogene. 2004 Oct 18;23(48):7918-27
pubmed: 15489910
Oncogene. 2020 May;39(21):4183-4197
pubmed: 32291412
CA Cancer J Clin. 2021 May;71(3):209-249
pubmed: 33538338
J Invest Surg. 2022 Feb;35(2):308-314
pubmed: 33289585
Oncogene. 2015 Apr 9;34(15):1919-27
pubmed: 24882577
Br J Cancer. 2008 Dec 2;99(11):1769-74
pubmed: 19018258
Oncol Lett. 2017 Jul;14(1):951-957
pubmed: 28693257
Expert Rev Anticancer Ther. 2021 Jun;21(6):657-671
pubmed: 33472018
Cancer Res. 1995 Jan 15;55(2):237-41
pubmed: 7812951
Biochim Biophys Acta. 2002 Jun 21;1602(2):114-30
pubmed: 12020799
Biomed Pharmacother. 2018 Oct;106:523-531
pubmed: 29990840
Methods. 2001 Dec;25(4):402-8
pubmed: 11846609
Mol Biol Cell. 2001 Jul;12(7):2171-83
pubmed: 11452011
Mol Cancer Ther. 2009 Jul;8(7):1924-33
pubmed: 19567819
Oncol Lett. 2018 Feb;15(2):2085-2090
pubmed: 29434909
Nat Rev Cancer. 2004 Jun;4(6):470-80
pubmed: 15170449
Transl Oncol. 2020 Nov;13(11):100841
pubmed: 32763503
Oncol Lett. 2021 Feb;21(2):150
pubmed: 33552268
Pharmacol Rev. 2012 Jul;64(3):706-21
pubmed: 22659329
Clin Cancer Res. 2008 Mar 1;14(5):1291-5
pubmed: 18316546
Oncogene. 2012 Apr 12;31(15):1869-83
pubmed: 21892204
Mini Rev Med Chem. 2002 Apr;2(2):103-11
pubmed: 12370072
Mol Cancer Ther. 2013 Oct;12(10):2157-66
pubmed: 23956056